Autophagic protein Beclin 1 serves as an independent positive prognostic biomarker for non-small cell lung cancer.
Autophagic protein Beclin 1 serves as an independent positive prognostic biomarker for non-small cell lung cancer.
复制标题
自噬蛋白 Beclin 1 作为非小细胞肺癌的独立阳性预后生物标志物
DOI：
10.1371/journal.pone.0080338
复制
发表时间：
2013
期刊：
影响因子：
3.7
通讯作者：
Liu A
中科院分区：
文献类型：
--
作者：
Zhou W;Yue C;Deng J;Hu R;Xu J;Feng L;Lan Q;Zhang W;Ji D;Wu J;Liu Q;Liu A
Beclin 1是自噬的关键调节因子，已被发现在多种人类恶性肿瘤中异常表达。本研究采用免疫组化（IHC）方法检测Beclin 1蛋白在非小细胞肺癌（NSCLC）及配对的正常邻近肺组织中的表达，并分析其在NSCLC中的临床病理/预后意义。利用受试者工作特征（ROC）曲线分析确定训练集（n = 105） Beclin 1表达的截断点（>2 VS.≤2）。为了验证roc衍生的截止值，在测试集（n = 111）和整体患者队列（n = 216）中分析Beclin 1与患者临床特征和结局的关系。我们的数据显示，Beclin 1在非小细胞肺癌组织中的表达明显低于邻近正常组织，与肿瘤复发率呈负相关（65.8% VS 32.3%, p < 0.001）。在测试集和整体患者队列中，Beclin 1低表达与Beclin 1高表达相比，总生存期（OS） （p < 0.001）和无进展生存期（PFS） （p < 0.001）明显低于。在测试集和整体患者队列中，Beclin 1高表达和低表达患者的中位OS持续时间分别为108对24.5个月（p < 0.001）和108对28个月（p < 0.001）。此外，Beclin 1的低表达也是NSCLC患者各阶段预后不良的因素。多因素分析表明Beclin 1是NSCLC的独立预后因素。我们在本研究中的发现提供了证据，证明Beclin 1可能因此在未来成为这种肿瘤实体的独立预后生物标志物。
Beclin 1, a key regulator of autophagy, has been found to be aberrantly expressed in a variety of human malignancies. Herein, we employed immunohistochemistry (IHC) to detect the protein expression of Beclin 1 in non-small cell lung cancer (NSCLC) and paired normal adjacent lung tissues, and analyzed its clinicopathological/prognostic significance in NSCLC. Receiver operating characteristic (ROC) curve analysis was utilized to determine a cutoff point (>2 VS. ≤2) for Beclin 1 expression in a training set (n = 105). For validation, the ROC-derived cutoff value was subjected to analysis of the association of Beclin 1 with patients’ clinical characteristics and outcome in a testing set (n = 111) and the overall patient cohort (n = 216). Our data showed that Beclin 1 was significantly lower in NSCLC tissues compared with the adjacent normal tissues, negatively associating with tumor recurrence rate (65.8% VS 32.3%; p < 0.001). In the testing set and the overall patient cohort, low expression of Beclin 1 showed significantly inferior overall survival (OS) (p < 0.001) and progression-free survival (PFS) (p < 0.001) compared to high expression of Beclin 1. In the testing set and the overall patient cohort, the median duration of OS for patients with high and low expression of Beclin 1 was 108 VS. 24.5 months (p < 0.001) and 108 VS. 28 months (p < 0.001), respectively. Furthermore, low expression of Beclin 1 was also a poor prognostic factor within each stage of NSCLC patients. Multivariate analysis identified that Beclin 1 was an independent prognostic factor for NSCLC. Our findings in the present study provided evidence that Beclin 1 may thus emerge as an independent prognostic biomarker in this tumor entity in the future.
登录
查看更多内容
影响因子：
10.5
作者：
Mathew, Robin;Kongara, Sameera;White, Eileen
通讯作者：
White, Eileen
影响因子：
2.8
作者：
Jiang, Zi-Feng;Shao, Li-Jie;Liu, Rong-Yu
通讯作者：
Liu, Rong-Yu
影响因子：
78.5
作者：
Mathew, Robin;Karantza-Wadsworth, Vassiliki;White, Eileen
通讯作者：
White, Eileen
影响因子：
3.7
作者：
Lokk K;Vooder T;Kolde R;Välk K;Võsa U;Roosipuu R;Milani L;Fischer K;Koltsina M;Urgard E;Annilo T;Metspalu A;Tõnisson N
通讯作者：
Tõnisson N
Beclin 1 依赖性细胞凋亡活性在肝细胞癌中的预后意义
影响因子：
13.3
作者：
Shi, Ying-Hong;Ding, Zhen-Bin;Fan, Jia
通讯作者：
Fan, Jia